Reslizumab
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Reslizumab: From Eosinophilic Asthma to Immune Thrombocytopenia
One-Sentence Summary
Reslizumab is an anti-IL-5 monoclonal antibody originally developed for eosinophilic asthma. The TxGNN model predicts it may be effective for Immune Thrombocytopenia (thrombocytopenia due to immune destruction), but currently no clinical trials and no directly relevant literature support this prediction — the score reflects an indirect knowledge-graph association rather than established pharmacology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Eosinophilic asthma (per drug mechanism description; not on file in Taiwan licenses — drug is not marketed) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (MOA: Data Gap). Based on known information, Reslizumab is an anti-IL-5 monoclonal antibody that inhibits eosinophil production and activation, and its efficacy in eosinophilic asthma is well established.
However, the repurposing rationale for immune thrombocytopenia explicitly notes that no known mechanism links the IL-5 pathway to megakaryocyte function or immune-mediated platelet destruction. The high TxGNN score appears to stem from an indirect knowledge-graph connection — likely through general immune-modulation or autoimmune-related nodes — rather than any documented molecular or clinical pathway. There is no direct pharmacological rationale connecting eosinophil suppression to platelet immune destruction at this time.
A secondary, lower-ranked prediction ("primary release disorder of platelets") is supported only by a single review article on mepolizumab (a different anti-IL-5 agent) in hypereosinophilic syndrome, which does not address reslizumab or platelet release mechanisms directly. This further indicates the current evidence base for platelet-related indications is speculative rather than substantive.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Reslizumab is currently not marketed in Taiwan (0 authorizations on file). No license or approved-indication records are available for reference.
Safety Considerations
Please refer to the package insert for safety information. (TFDA warnings/contraindications and drug interaction data are not yet available — see data gap DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (Evidence Level L5), with no clinical trials, no directly relevant literature, and no established mechanistic link between the IL-5 pathway and immune-mediated platelet destruction. There is insufficient evidence to advance this candidate.
To proceed, the following is needed:
- Reslizumab MOA detail from DrugBank (data gap DG002)
- TFDA package insert warnings/contraindications (data gap DG001, blocking for S1 safety review)
- Preclinical or mechanistic studies directly linking IL-5/eosinophil biology to platelet immune destruction
- Any case reports or observational data on reslizumab use in patients with concurrent thrombocytopenia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.